Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected to Post Earnings of -$0.27 Per Share

Wall Street analysts expect Outlook Therapeutics, Inc. (NASDAQ:OTLK) to post earnings of ($0.27) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Outlook Therapeutics’ earnings. Outlook Therapeutics posted earnings per share of ($1.60) during the same quarter last year, which would indicate a positive year over year growth rate of 83.1%. The business is expected to issue its next quarterly earnings results on Tuesday, August 13th.

On average, analysts expect that Outlook Therapeutics will report full-year earnings of ($1.54) per share for the current financial year. For the next fiscal year, analysts expect that the business will post earnings of ($0.69) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Outlook Therapeutics.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.08. The firm had revenue of $0.64 million during the quarter.

A number of equities research analysts have recently issued reports on the stock. Ascendiant Capital Markets assumed coverage on shares of Outlook Therapeutics in a research note on Monday, April 22nd. They issued a “buy” rating and a $4.00 target price on the stock. HC Wainwright started coverage on shares of Outlook Therapeutics in a report on Thursday, July 18th. They set a “buy” rating and a $8.00 price objective for the company. Oppenheimer started coverage on shares of Outlook Therapeutics in a report on Thursday, May 16th. They set an “outperform” rating and a $12.00 price objective for the company. ValuEngine raised shares of Outlook Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, CIBC started coverage on shares of Outlook Therapeutics in a report on Thursday, May 16th. They set an “outperform” rating and a $12.00 price objective for the company. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $9.00.

A hedge fund recently bought a new stake in Outlook Therapeutics stock. Chicago Capital LLC acquired a new stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 19,450 shares of the company’s stock, valued at approximately $40,000. Chicago Capital LLC owned about 0.07% of Outlook Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 0.87% of the company’s stock.

Shares of Outlook Therapeutics stock traded up $0.14 during trading on Wednesday, reaching $2.26. The company had a trading volume of 300 shares, compared to its average volume of 1,798,948. The firm has a market capitalization of $60.13 million, a P/E ratio of -0.21 and a beta of -0.86. The firm’s fifty day simple moving average is $2.19. Outlook Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $10.96.

About Outlook Therapeutics

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Recommended Story: What does earnings per share mean?

Get a free copy of the Zacks research report on Outlook Therapeutics (OTLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.